ASCO 2012: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial
Category: Presentation
AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib
AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib
AACR-NCI-EORTC 2011: A Phase I Study to Evaluate the Absorption, Metabolism and Excretion of the Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Tivozanib
AACR-NCI-EORTC 2011: A Phase I Study to Evaluate the Absorption, Metabolism and Excretion of the Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Tivozanib
AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors
AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors
AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade
AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade
EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC
EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC
ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma
ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma
ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma
ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma
ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer
ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer
ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC